Ratings Carl Zeiss Meditec AG Berne S.E.

Equities

AFX

DE0005313704

Delayed Berne S.E. 09:30:00 08/04/2024 pm IST 5-day change 1st Jan Change
104.7 CHF -10.65% Intraday chart for Carl Zeiss Meditec AG -10.65% +12.25%

Summary

  • The company has strong fundamentals. More than 70% of companies have a lower mix of growth, profitability, debt and visibility.

Strengths

  • The average target price set by analysts covering the stock is above current prices and offers a tremendous appreciation potential.
  • The group usually releases upbeat results with huge surprise rates.

Weaknesses

  • The company's earnings growth outlook lacks momentum and is a weakness.
  • The company's valuation in terms of earnings multiples is rather high. Indeed, the firm is getting paid 29.59 times its estimated earnings per share for the ongoing year.
  • The company's enterprise value to sales, at 3.56 times its current sales, is high.
  • The company appears highly valued given the size of its balance sheet.
  • The company is highly valued given the cash flows generated by its activity.
  • The firm pays small or no dividend to shareholders. For that reason, it is not a yield company.
  • Over the past twelve months, analysts' consensus has been significantly revised downwards.
  • The price targets of various analysts who make up the consensus differ significantly. This reflects different assessments and/or a difficulty in valuing the company.

Ratings chart - Surperformance

Sector: Advanced Medical Equipment & Technology

1st Jan change Capi. Investor Rating ESG Refinitiv
+12.25% 806.96Cr -
+7.77% 22TCr
B
+10.16% 19TCr
B-
+26.21% 15TCr
B-
+32.78% 11TCr
A-
+1.98% 6.4TCr
A-
+14.48% 5.26TCr
B+
+2.92% 4.99TCr
B+
-6.60% 3.79TCr
A
-1.07% 3.49TCr -
Investor Rating
Trading Rating
ESG Refinitiv
-

Financials

Sales growth
Earnings Growth
EBITDA / Sales
Profitability
Finances

Valuation

P/E ratio
EV / Sales
Price to Book
Price to Free Cash Flow
Yield

Momentum

1 year Revenue revision
4 months Revenue revision
7 days Revenue revision
1 year EPS revision
4 months EPS revision

Consensus

Analyst Opinion
Potential Price Target
4m Target Price Revision
4m Revision of opinion
12m Revision of opinion

Business Predictability

Analyst Coverage
Divergence of Estimates
Divergence of analysts' opinions
Divergence of Target Price
Earnings quality

Technical analysis

ST Timing
MT Timing
LT Timing
RSI
Bollinger Spread
Unusual volumes
  1. Stock Market
  2. Equities
  3. AFX Stock
  4. AFX Stock
  5. Ratings Carl Zeiss Meditec AG